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Abstract
Purpose To systematically assess patterns and temporal changes in the measurement and valuation of childhood health 
utilities and associations between methodological factors.
Methods Studies reporting childhood health utilities using direct or indirect valuation methods, published by June 2017, 
were identified through PubMed, Embase, Web of Science, PsycINFO, EconLit, CINAHL, Cochrane Library and PEDE. The 
following were explored: patterns in tariff application; linear trends in numbers of studies/samples and paediatric cost–utility 
analyses (CUAs) and associations between them; changes in proportions of studies/samples within characteristic-based cat-
egories over pre-specified periods; impact of National Institute for Health and Care Excellence (NICE) guidance on primary 
UK research and associations between valuation method, age and methodological factors.
Results 335 studies with 3974 samples covering all ICD-10 chapters, 23 valuation methods, 12 respondent types and 42 
countries were identified by systematic review. 34.0% of samples using indirect methods compatible with childhood applied 
childhood-derived tariffs. There was no association between numbers of studies/samples and numbers of CUAs. Compared 
to 1990–2008, 2009–June 2017 saw a significant fall in the proportion of studies using case series; significant compositional 
changes across ICD-10 chapters and significantly higher sample proportions using childhood-specific and adult-specific 
indirect valuation methods, and based on pre-adolescents, self-assessment, self-administration and experienced health states. 
NICE guidance was weakly effective in promoting reference methods. Associations between valuation method, age and 
methodological factors were significant.
Conclusion 1990–2017 witnessed significant changes in primary research on childhood health utilities. Health technology 
assessment agencies should note the equivocal effect of methodological guidance on primary research.
Keywords Systematic review · PRISMA · Childhood health states · Health utility · Economic evaluation · Cost–utility 
analysis
Introduction
Sustained health budget constraints necessitate the compari-
son of alternative programmes and interventions in terms 
of costs and consequences [1]. Cost–utility analysis (CUA) 
remains the preferred form of economic evaluation aimed 
at informing the allocation of finite resources for decision-
making agencies around the world [2–6]. In CUA, the qual-
ity-adjusted life-year (QALY) is the preferred measure of 
health outcome where the QALY combines preference-based 
health-related quality of life (HRQoL) outcomes, or health 
utility values, associated with health states, with the length 
of time in those states [7]. The generic nature of health 
utilities (and thus QALYs) allows comparison of health-
care interventions across disparate health conditions and 
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populations. Health utilities are indexed on a cardinal scale 
where 0 represents death and 1 represents perfect health [1].
Valuation methods for utility assessment can be divided 
into two broad categories: direct and indirect. Direct meth-
ods combine the valuation and measurement process into 
a single step, and include the standard gamble (SG) tech-
nique and the time trade-off (TTO) approach [1]. The visual 
analogue scale (VAS) is another direct valuation method, 
although considered by some economists not to be a health 
utility measurement approach since the valuation procedure 
is not choice based and does not involve decision making 
under uncertainty [8]. Indirect valuation methods use multi-
attribute utility instruments (MAUIs) such as the EQ-5D [9], 
Health Utilities Index (HUI) [10], SF-6D [11], Quality of 
Well-Being Scale (QWB) [12] and Assessment of Quality of 
Life (AQoL or AQoL-5D) [13]. MAUIs ask respondents to 
describe their health state using a health status classification 
system containing several dimensions, each with multiple 
levels. Algorithms, or tariff sets, elicited from representa-
tive populations using direct valuation methods such as the 
TTO, are then applied to convert responses into health utility 
values.
Unique methodological challenges arise when utility 
assessments are conducted for childhood (age < 18 years) 
health conditions or states [14, 15]. For example, infants 
(age < 2 years), as well as pre-adolescents (age < 12 years) 
and adolescents (age ≥ 12 and < 18 years) with develop-
mental delays or cognitive deficits arising from neurode-
velopmental disorders, lack comprehension to complete 
direct or indirect valuation methods, thus requiring proxy 
assessment. Moreover, bio-psychosocial development dur-
ing childhood means that dimensions relevant to HRQoL 
change rapidly by age [16]. This means that classification 
systems embedded into adult-specific MAUIs (targeted at 
those aged ≥ 18 years), such as the EQ-5D and SF-6D, may 
not incorporate health dimensions relevant to developmental 
stages through childhood. MAUIs with childhood-specific 
classification systems have been developed to meet this 
challenge, including the EQ-5D-Y (Youth) [17], 16-Dimen-
sional Health-Related Measure (16D) [18], 17-Dimensional 
Health-Related Measure (17D) [19], AQoL-6D [20] and 
Child Health Utility 9-Dimensions (CHU9D) [21]. Moreo-
ver, several MAUIs, such as the HUI2, HUI3 and QWB, 
have classification systems compatible with both adult and 
childhood health states. Many measures with classification 
systems designed specifically for or compatible with child-
hood, such as the EQ-5D-Y, HUI3 and QWB, rely on tariffs 
derived from adult populations. Thus, another methodologi-
cal concern relates to potential differences between children 
and adults in how they value health states contained within 
MAUIs [22].
There has been increasing recognition of these meth-
odological challenges in international health technology 
assessment (HTA) guidelines. The 2013 National Institute 
for Health and Care Excellence (NICE) methods guid-
ance recognised that its preferred measure, the EQ-5D, 
lacked a classification system designed for use in children 
and recommended use of the EQ-5D-Y for children aged 
7–12 years, although no separate tariff set for this measure 
existed [2]. The 2016s US Panel on Cost-effectiveness in 
Health and Medicine acknowledged the challenges sur-
rounding childhood utility measurement and discussed the 
relative advantages of alternative instruments, including 
HUI2/3, EQ-5D-Y and CHU9D, but without recommend-
ing a preferred approach [6]. Despite these developments, 
adult-specific health utilities are still frequently applied 
to childhood health states within economic evaluations. 
Montgomery and Kusel [23] reviewed all NICE health 
technology appraisals in England until June 2015 and 
identified 29 submissions directly related to paediatric 
health, only six of which applied childhood-specific utili-
ties. It is generally unclear how developments of national 
HTA guidelines have influenced priorities and designs, 
including choice of valuation methods, in primary assess-
ments of childhood health utilities.
In line with the preference of several HTA agencies, CUA 
is now the leading analytic approach for economic evalua-
tion of health interventions targeting children, with the num-
ber of CUAs overtaking that of cost-effectiveness analyses 
(CEAs) contained in the Paediatric Economic Database 
Evaluation (PEDE) in 2009 [24]. Although health utility 
data constitute vital inputs into CUAs, it is rare for analysts 
to estimate utility values using primary research methods 
unless the economic evaluation is conducted alongside 
a prospectively designed study with individual-level data 
[25]. Decision-analytic models typically contain several 
health states of interest that require sourcing of utility esti-
mates from primary studies or systematic reviews. In such 
cases, the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) guideline [26] recommends 
that analysts identify and extract health utilities from mul-
tiple sources in the published literature and synthesise if 
appropriate.
Catalogues and reviews of health utility values for child-
hood populations are available, but have largely focussed 
on a relatively small number of conditions, such as acute 
lymphoblastic leukaemia [27, 28], asthma [29], neuro-
disability [30] and childhood obesity [31], or on a single 
valuation source, such as EQ-5D [32], HUI3 [33] and SG 
[34]. The PEDE project is an alternative source of child-
hood health utility values and contains 2112 values from 
857 CUAs in paediatric populations published between 
1980 and 2016 [35]. However, only 8.5% (n = 73) of these 
CUAs conducted primary estimation of utility values [36]. 
Furthermore, published CUAs represent only one source of 
childhood health utility values.
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This paper addresses three aims against a backdrop of 
rapid development of measurement approaches and methods 
guidance in this area. First, it systematically describes the 
patterns of primary studies and samples measuring child-
hood health utilities, by study design and sample charac-
teristics, as well as patterns in the source of tariffs when 
MAUIs compatible with or specific to children are used. 
Second, linear trends in the numbers of studies and samples, 
their associations with the number of paediatric CUAs and 
changes in proportions of studies and samples before and 
after key transition timepoints are explored. Third, associa-
tions between valuation methods and sample age and other 
methodological factors are explored.
Methods
Systematic review
The systematic review followed PRISMA guidelines [37] 
and covered all studies published by 30th June 2017. The 
search strategy (Supplementary Material Table S1), inclu-
sion and exclusion criteria and databases included—Pub-
Med, Embase of OVID Medline, Web of Science, Psy-
cINFO, Cochrane Library, CINAHL and EconLit—were 
based on the study by Kwon and colleagues [38], which 
covered a period up to 31 December 2015 and focused 
only on static descriptions of included studies and samples 
alongside a meta-regression of childhood utility values. The 
search strategy was developed and piloted prior to imple-
mentation and included an intersection of health utility, 
valuation method and childhood search terms. Non-English 
language articles were excluded. The PEDE database was 
also searched to identify CUAs published between 1980 and 
2016 that incorporated primary estimation of health utilities.
Articles that met the inclusion criteria were English lan-
guage primary studies reporting health utilities for child-
hood populations or for childhood conditions or descriptors 
using direct or indirect valuation methods. Two reviewers 
(JK and SWK) independently assessed titles and abstracts. 
Articles with two approvals proceeded to the next stage; 
those with one were referred to a third reviewer (SP) for 
arbitration. At the second stage, the same primary reviewers 
analysed full-text articles with disagreements referred to the 
third reviewer. Conference abstracts were included if they 
reported original health utilities. Studies reporting primary 
VAS values were included despite disagreement about their 
validity for QALY construction [39].
Data extraction
From each study that met the inclusion criteria, the vari-
ables listed in Supplementary Material Table  S2 were 
extracted using a proforma. These included bibliographic 
details, study design, study setting, valuation method, tariff 
applied to MAUIs (including source population and valua-
tion method), respondent type, administration mode, sample 
target age(s), whether the health state was experienced or 
hypothetical, sample size and geographic setting. An Inter-
national Classification of Diseases 10th revision (ICD-10) 
code was allocated to each sample according to the health 
condition studied.
Descriptive analyses
The distribution of mean and median utility and VAS 
(rescaled to 0–1) scores extracted from included samples 
was calculated. The number of studies and samples by 
publication year was estimated together with the annual 
number of CUAs included in the PEDE database. Valua-
tion methods applied to studies within each ICD-10 chap-
ter were described. The numbers of samples by respond-
ent type, administration mode, target age(s) of sample and 
geographical factors (including continent of origin and 
national income levels, with income classification taken 
from the World Bank [40]) were estimated. Study designs 
and valuation methods were grouped into key categories. For 
application of MAUIs that are compatible with or specific 
to childhood populations, the tariffs applied and sources of 
their values (age group and setting/nationality) and valua-
tion method (e.g. VAS, SG, TTO) were described by MAUI.
Statistical analyses
Linear regression tested for linear trends in numbers of 
PEDE-based CUAs, utility studies and utility samples by 
year of publication. Controlling for these annual trends, 
associations between number of PEDE-based CUAs and 
number of utility studies and samples were also estimated. 
We tested the hypothesis that there were significant changes 
to the composition of childhood utility data categorised by 
study- and sample-level characteristics, including study 
design, health condition, valuation method, age of target 
population, respondent type, administration mode and valua-
tion of hypothetical health states. Tests of proportions, at the 
95% confidence level, were used to assess whether the pro-
portion in each category of study- and sample-level charac-
teristic changed significantly before and after a pre-specified 
transition point of 2009, which was when CUAs became the 
prominent analytic approach for paediatric economic evalu-
ations within the PEDE database [24]. In a separate analysis 
involving only UK studies and samples, 2013 was specified 
as a transition point when NICE identified EQ-5D-Y as its 
reference instrument for utility assessment in children aged 
7–12 years, while reaffirming EQ-5D as its reference instru-
ment for those aged 13 years and over [2]. The hypothesis 
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was that the guidance had a significant effect on the design 
of UK-based primary studies marked by a greater proportion 
of samples using the EQ-5D-Y for pre-adolescent popula-
tions (age < 12 years) and smaller proportions using non-ref-
erence direct or indirect valuation methods. Finally, two-way 
Pearson’s Chi-square tests were used at the 95% confidence 
level to assess the associations between valuation method 
and sample age, respondent type, administration mode and 
valuation of hypothetical health states. The hypothesis tested 
was that there are significant associations between methodo-
logical factors selected by researchers.
Results
Systematic review
Figure 1 presents the PRISMA flow diagram for the system-
atic review. The main reasons for exclusion were secondary 
studies using decision-analytic models, previous systematic 
reviews (which were kept for manual searching), targeting 
of adult populations and focus on non-preference-based 
health outcome measures. A total of 274 articles were 
included for data extraction. Manual searching yielded 45 
further articles, whilst a search of PEDE yielded a further 
16 articles. In total, data were extracted from 335 articles, 
which are summarised by health condition, intervention 
type (where applicable), country of study population, 
valuation method, respondent type, administration mode 
and age of target population in Supplementary Material 
Table S3.
Descriptive analyses
Distribution of sample means and medians
Descriptive statistics for health utilities were extracted from 
3974 samples contained within the 335 studies. The majority 
of studies (306 out of 335) contained two or more samples 
delineated by health condition/state, sociodemographic fac-
tors (e.g. gender, age) or methodological factors. Figure 2a 
depicts the frequency distribution of 3573 mean utility and 
VAS scores (excluding 191 samples, which only reported 
mean change in utility scores or regression coefficients) with 
each bar stratified by valuation method, while Fig. 2b does 
so for 870 median utility and VAS scores (some samples 
report both mean and median scores). The difference in dis-
tributional characteristics between mean and median scores 
is visible, with the negative skew much greater in median 
scores. Among samples reporting mean scores, 0.34% (12 
out of 3573) demonstrated the ceiling effect, namely a mean 
score of 1. The corresponding proportion was 7.36% (64 
out of 870) among samples reporting median scores. From 
visual inspection, there appears to be greater concentrations 
of trade-off-based direct valuation methods (TTO, SG and 
their variants) at the upper end of both mean and median 
Fig. 1  PRISMA flow diagram. 
Note PRISMA: Preferred 
reporting items for systematic 
reviews and meta-analyses. 
HRQoL Health-related quality 
of life. PEDE paediatric eco-
nomic database evaluation
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utility score ranges. Trade-off-based direct valuation meth-
ods comprised 17.9% of all samples generating mean util-
ity scores higher than 0.800, but 10.5% of all samples with 
mean scores ≤ 0.800. The corresponding proportions were 
33.0% and 14.0% for all median utility scores higher than 
0.800 and ≤ 0.800, respectively.
Fig. 2  a Distribution of mean utility and VAS scores (n = 3573) by 
valuation method. Note VAS: visual analogue scale; TTO: time 
trade-off; SG: standard gamble; MAUI: multi-attribute utility instru-
ment; NPB: utility mapped from non-preference-based instrument. 
b Distribution of median utility and VAS scores (n = 870) by valua-
tion method. Note VAS visual analogue scale, TTO time trade-off, SG 
standard gamble, MAUI multi-attribute utility instrument
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Distribution of samples by health condition and valuation 
method
Table 1 summarises the distribution of included samples by 
ICD-10 chapter. All ICD-10 chapters relevant to childhood 
health were covered by samples included in the systematic 
review. The ICD-10 mental and behavioural disorders chap-
ter contained the highest number of samples (n = 698), fol-
lowed by general childhood population health (n = 501) and 
cancer (n = 442). Across all ICD-10 chapters, 180 unique 
ICD-10 codes were used to label samples.
Twenty-three unique valuation methods were identified. 
These were grouped into six key categories: (i) VAS—
EQ-5D VAS (number of samples = 348; 8.8%), EQ-5D-Y 
VAS (n = 232; 5.8%) and stand-alone VAS (n = 252; 
6.3%); (ii) trade-off-based direct valuation methods—TTO 
(n = 171; 4.3%), SG (n = 227; 5.7%), chained gamble and 
adjusted SG (n = 143; 3.6%); (iii) adult-specific MAUIs—
EQ-5D (n = 424; 10.7%), SF-6D (n = 34; 0.9%), AQoL-5D 
(n = 16; 0.4%) and 15D (n = 2; 0.05%); (iv) MAUIs com-
patible with both childhood and adult populations—QWB 
(n = 224; 5.6%), HUI2 (n = 482; 12.1%), HUI3 (n = 822; 
20.7%), modified HUI (10-dimension variant of HUI 
[41], HUI3 with ‘worst imaginable health’ as 0 instead of 
death [42]; n = 8; 0.2%) and ABC-UI (Aberrant Behaviour 
Checklist Utility Index) [43] (n = 1; 0.03%); (v) childhood-
specific MAUIs—EQ-5D-Y (n = 108; 2.7%), CHU9D 
(n = 231; 5.8%), 16D (n = 73; 1.8%), 17D (n = 39; 1.0%), 
AQoL-6D (n = 50; 1.3%), PAHOM (Pediatric Asthma 
Health Outcome Measure) [44] (n = 69; 1.7%) and CH-6D 
(Child Health-6 Dimensions) [45] (n = 3; 0.08%);and (vi) 
mapping non-preference-based clinical measures to utility 
indices [46–50] (n = 15; 0.4%).
Table 1  Number of samples by ICD-10 chapter and the most frequently used valuation methods by ICD-10 chapter (% of samples in chapter)
No samples were found for ICD-10 chapter 15 for pregnancy, childbirth and puerperium; chapter 16 for symptoms, signs and abnormal clinical 
and laboratory findings, not elsewhere classified and chapter 20 for external causes of morbidity and mortality. These chapters were deemed not 
directly relevant to childhood health. The ‘general health’ category included samples measuring utility in general paediatric populations drawn 
from the general community or schools or in control groups of healthy children from observational and experimental studies. Chapter 21 classi-
fies samples by contact with health services rather than disease type. These samples are drawn from studies delineated by interventions or pro-
grammes and a health condition is not specified. The ‘combined chronic diseases’ category included samples comprising children with diverse 
chronic conditions
General health: 501
CHU9D (27.4)
EQ-5D-Y VAS (24.4)
EQ-5D-Y (10.6)
Chapter 1 Infectious and parasitic diseases: 
195
VAS (24.1)
EQ-5D (15.9)
TTO (15.4)
Chapter 2 Cancer: 442
HUI2 (52.0)
HUI3 (37.1)
VAS (2.94)
Chapter 3 Diseases of blood: 85
SG (43.5)
EQ-5D (24.7)
VAS (12.9)
Chapter 4 Endocrine, nutritional and metabolic 
disorders: 411
SG (14.1)
HUI3 (12.9)
EQ-5D-Y VAS (12.4)
Chapter 5 Mental and behavioural disorders: 
698
EQ-5D (20.2)
HUI3 (18.9)
EQ-5D VAS (16.6)
Chapter 6 Nervous system disorders: 114
HUI3 (43.0)
SF-6D (9.65)
EQ-5D (7.89)
Chapter 7 Diseases of the eye: 61
TTO (42.6)
Chained Gamble (42.6)
HUI3 (14.8)
Chapter 8 Diseases of the ear: 158
HUI3 (58.2)
VAS (13.3)
HUI2 (6.96)
Chapter 9 Circulatory system disorders: 16
VAS (31.3)
HUI3 (31.3)
HUI2 (18.8)
Chapter 10 Respiratory system disorders: 192
PAHOM (35.8)
EQ-5D VAS (16.8)
EQ-5D (12.1)
Chapter 11 Digestive system disorders: 60
16D/17D (20.0)
EQ-5D-Y VAS (18.3)
CHU9D (16.7)
Chapter 12 Diseases of the skin: 26
VAS (38.5)
TTO (26.9)
EQ-5D (15.4)
Chapter 13 Musculoskeletal system disorders: 
114
EQ-5D (37.7)
EQ-5D VAS (17.5)
VAS (14.9)
Chapter 14 Genitourinary system disorders: 56
VAS (30.4)
TTO (26.8)
HUI3 (16.1)
Chapter 16 Conditions originating in perina-
tal period: 210
HUI3 (38.1)
SG (33.3)
HUI2 (15.7)
Chapter 17 Congenital malformations: 155
HUI3 (33.6)
VAS (23.2)
TTO (18.1)
Chapter 19 Injury, poisoning and other conse-
quences of external causes: 297
QWB (40.7)
EQ-5D (29.0)
EQ-5D VAS (13.1)
Chapter 21 Contact with health services: 80
HUI3 (48.8)
HUI2 (36.3)
15D/16D/17D (8.75)
Combined chronic diseases: 103
HUI3 (40.8)
EQ-5D-Y VAS (23.3)
EQ-5D VAS (12.6)
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Table 1 describes the three most frequently used valua-
tion methods by ICD-10 chapter. HUI2 or HUI3 was used 
by 89.1% of cancer samples, which is consistent with these 
measures originally being developed for paediatric cancer 
patients and survivors [51, 52]. Childhood-specific MAUIs 
represented the most frequently used valuation method 
for only 3 out of 20 chapters: CHU9D (27.4% for general 
health), PAHOM (35.8% for respiratory system disor-
ders) and 16D/17D (20.0% for digestive system disorders). 
MAUIs compatible with childhood and adult populations 
were the most frequently used methods for eight chapters: 
HUI2 for chapter 2, HUI3 for Chaps. 6, 8, 16, 17 and com-
bined chronic diseases and QWB for chapter 19.
Distribution of samples by methodological factors, age 
and geographical setting
Table 2 presents the number of study samples by respondent 
type, administration mode, target age of children and geo-
graphical setting. Thirty-seven percent of samples (n = 1498) 
used self-assessment by children. A total of 456 samples 
(11.5%) allowed children to generate responses together 
with proxies. The remainder of the samples relied on proxy 
assessment, most commonly by parents (n = 1091; 27.5%). 
Administration modes fell broadly into two categories: (i) 
self-administered surveys in school or clinical settings, by 
mail, online or by Delphi elicitation of clinicians [53]; and 
(ii) interview-administered surveys by face-to-face meeting 
or by telephone. Target age groups spanned the whole age 
spectrum of childhood. Six percent of samples contained 
infants (aged < 2 years), while some samples (n = 41) had a 
minimum age of 18 years even though they specified adoles-
cents as the target group. A significant proportion of samples 
(14.4%) did not report any information on age. As for geo-
graphical setting, the skew towards high-income countries 
was clear (91.6%). The US produced the highest number 
of samples (n = 970; 24.4%) followed by Canada (n = 674; 
17.0%) and the UK (n = 634; 16.0%).
MAUIs and tariff application
Table 3 lists the tariffs that were used in applications of 
MAUIs compatible with or specific to childhood popula-
tions and their valuation populations and methods. All 16D 
and 17D samples that provided information applied tariffs 
derived from children or their proxies (Finnish schoolchil-
dren aged 12–16 years using VAS [19] for 16D or their prox-
ies (Finnish parents of children aged 8–11 years) using VAS 
[20] for 17D). For AQoL-6D, 72.0% of samples applied 
adolescent-derived tariffs [54], while 28.0% applied the 
general adult-derived tariff [55]. Adolescent-derived tar-
iffs [56, 57] were used in 46.3% of CHU9D samples and 
general adult-derived tariffs [58] in 52.8%. Only a single 
EQ-5D-Y sample applied childhood-derived tariffs [59], 
while 78.7% of samples applied general adult-derived tar-
iffs from 10 countries [60–67]. Overall, 54.3% of samples 
using childhood-specific MAUIs applied childhood-derived 
tariffs, 40.0% applied adult-derived tariffs and 5.7% gave no 
information on underpinning tariffs. For MAUIs compatible 
with both childhood and adult populations, 26.4% of sam-
ples applied childhood-derived tariffs, while 67.5% applied 
adult-derived tariffs. HUI2 offers both childhood- [68–70] 
and adult-derived [71] tariffs, while the HUI3, QWB and 
ABC-UI only offer adult-derived tariffs [72–74].
Statistical analyses
Linear trend in utility studies and samples and PEDE CUAs
Figure 3 jointly depicts trends in number of utility studies 
and samples and number of paediatric CUAs in the PEDE 
database. It also marks out years 2009 and 2013, which 
are the transition timepoints for the two separate periodic 
changes analysed below. The upward trends in all three 
groups are visible and confirmed by statistical tests for 
linear trend. The coefficients for year of publication were 
1.15 (95% confidence interval: 0.96 to 1.36; P < 0.001) 
for number of utility studies, 12.70 (95% CI 9.32 to 16.08; 
P < 0.001) for number of utility samples and 3.63 (95% CI 
3.01 to 4.25; P < 0.001) for number of PEDE CUAs. The 
number of utility studies increased at a steady rate across the 
whole review period, while the numbers of utility samples 
and PEDE CUAs increased markedly in the late 2000s.
Association between PEDE CUAs and utility studies 
and samples
Linear regression of the number of utility studies on number 
of CUAs, controlling for linear time trend, showed no asso-
ciation (coefficient on CUAs: 0.114; standard error 0.763; 
P value: 0.097). There was similarly no association between 
number of utility samples and number of CUAs (coefficient: 
0.624; SE: 1.189; P value: 0.605). No associations were 
similarly found between proportion of paediatric economic 
evaluations that were CUAs and the number of primary util-
ity studies and samples.
Periodic change in composition of utility studies 
and samples
Table 4 summarises the numbers of studies and samples 
by categories of study design, health condition, valuation 
method, target age, respondent type, administration mode 
and valuation of hypothetical health state. Supplementary 
Materials Tables S4-S7 present the results across 5-year 
publication intervals. Comparisons between two broader 
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periods, 1990–2008 and 2009–June 2017, saw a significant 
decline in the proportion of patient case series (10.2% point 
decrease; P = 0.013).
In terms of health condition, comparisons between the 
two periods revealed significant changes in proportion of 
samples in all ICD-10 chapters except musculoskeletal sys-
tem disorders. Categories that saw the greatest change were 
cancer (18.7% point decrease; P < 0.001), general health 
(15.1% point increase; P < 0.001), mental and behavioural 
disorders (12.1% point increase; P < 0.001) and injury 
(11.4% point decrease; P < 0.001).
There were equally significant changes for valuation 
method, respondent type, administration mode and valuation 
of hypothetical health states. For valuation method, child-
hood-specific MAUIs saw the greatest increase (15.6% point 
increase; P < 0.001) whilst trade-off-based direct valuation 
methods saw the greatest decrease (15.7% point decrease; 
P < 0.001). However, there was also a significant increase 
in the use of adult-specific MAUIs (4.5% point increase; 
P < 0.001) and VAS approaches (7.4% point increase; 
P < 0.001). MAUIs compatible with both childhood and 
adult populations experienced a significant decrease in use 
(12.0% point decrease; P < 0.001). There was a significant 
shift towards self-assessment of health status by children 
(24.0% point increase; P < 0.001), and the use of self-
administered surveys in school and clinic settings (29.9% 
point increase; P < 0.001). Similarly, there was a significant 
increase in the number of samples valuing experienced 
rather than hypothetical health states (16.8% point increase; 
P < 0.001). As for age of target population, there was a sig-
nificant shift in focus to pre-adolescent populations (4.2% 
point increase; P = 0.011) and a significant fall in the propor-
tion of samples failing to provide information on age (7.1% 
point decrease; P < 0.001).
Influence of HTA guidance on primary samples
Table 5 presents similar tests of proportions comparing two 
periods, 1990–2012 (before the publication of the 2013 
NICE HTA guidance) and 2013–June 2017, in 355 UK sam-
ples containing pre-adolescents (mean/median or minimum 
age 12 or below) and 207 UK samples not containing pre-
adolescents. Samples containing pre-adolescents increased 
significantly as a proportion of all samples from 45.0% 
in 1990–2012 to 85.1% in 2013–June 2017 (40.1% point 
increase; P < 0.001). Seventy-two samples in 1990–2012 
did not report age of target population compared to none 
in 2013–June 2017. The evidence supporting our hypoth-
esis that publication of the NICE guidance would increase 
the use of reference instruments in relevant age groups and 
reduce the use of non-reference instruments was mixed. For 
samples containing pre-adolescents, the use of EQ-5D-Y 
increased from 3.9% of samples in 1990–2012 to 16.9% in Ta
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Table 3  Multi-attribute utility instruments (MAUIs) developed for children and tariff valuation population and method
MAUI Target age range Tariff valuation population and method Number of 
samples (%)
Childhood-specific MAUIs
 16D 12–15 Finnish schoolchildren aged 12–16 (n = 213) using VAS [18] 68 (93.2)
No information or reference on tariff 5 (6.8)
 17D 8–11 (Proxy for < 8) Finnish parents of children aged 8–11 (n = 115) using VAS [19] 39 (100.0)
 AQoL-6D Adolescents 1. Australian adolescents (n = 2790) using TTO [69] 36 (72.0)
2. Australian general adult public (n = 411) using TTO [70] 14 (28.0)
 CHU9D 7–17 1. Australian adolescents aged 11–17 (n = 590) using best-worst scale 
discrete-choice experiment [71]
91 (39.4)
2. Australian adolescents aged 11–17 (n = 1982) using best-worst scale 
discrete-choice experiment [72]
16 (6.9)
3. UK general adult public (n = 300) using SG [73] 122 (52.8)
No information or reference on tariff 2 (0.9)
 EQ-5D-Y 8–15 (Proxy for 4–7) 1. Canadian elementary schoolchildren aged 10–11 (n = 4485) using 
VAS [74]
1 (0.9)
2. UK general adult public (n = 3395) using TTO [75] 25 (23.1)
3. Dutch general adult public (n = 309) using TTO [76] 9 (8.3)
4. Dutch general adult public (n = 303) using TTO [77] 5 (4.6)
5. Australian general adult public (n = 417) using TTO [78] 14 (13.0)
6. French general adult public (n = 452) using TTO [79] 3 (2.8)
7. Swedish general adult public (n = 45,000) using TTO and VAS [80] 4 (3.7)
8. General adult public from Finland, Germany, Netherlands, Spain, 
Sweden and UK (n = 6870) using VAS [81]
2 (1.9)
9. US general adult public using TTO [82] 23 (21.3)
No information or reference on tariff 22 (20.4)
 PAHOM 7–13 1. Asthmatic children aged 6–12 (n = 261) using SG [83] 60 (87.0)
2. US general adult public (n = 94) using VAS [44] 4 (5.8)
3. US general adult public (n = 101) using SG [44] 4 (5.8)
No information or reference on tariff 1 (1.4)
 CH-6D 16–18 No information or reference on tariff 3 (100.0)
MAUIs compatible with childhood and adult populations
 HUI2 ≥ 5 (Proxy for 5–8) 1. Canadian parents of schoolchildren (n = 194) using VAS and SG 
[84]
357 (74.1)
2. Canadian parents of normal children (n = 300) using VAS and SG 
[85]
22 (4.6)
3. Singaporean parents of paediatric cancer patients (n = 59) using 
VAS and SG [86]
10 (2.1)
4. Singaporean general public parents of children (n = 194) using VAS 
and SG [86]
10 (2.1)
5. UK general adult public (n = 201) using VAS and SG [87] 58 (12.0)
No information or reference on tariff 25 (5.2)
 HUI3 ≥ 5 (Proxy for 5–8) Canadian general adult public (n = 504) using VAS and SG [88] 753 (91.6)
No information or reference on tariff 69 (8.4)
 Modified HUI [39, 40] N/A 1. Canadian parents of schoolchildren (n = 194) using VAS and SG 
[84]
7 (87.5)
2. Canadian general adult public (n = 504) using VAS and SG [88] 1 (12.5)
 QWB N/A US general public (n = 800) using VAS [89] 224 (100.0)
 ABC-UI N/A (Proxy completed) UK general adult public (n = 349) using TTO [90] 1 (100.0)
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2013–June 2017 (13.0% point increase; P < 0.001). Moreo-
ver, the use of the non-reference HUI2/3 and trade-off-based 
instruments fell from 75.4% and 5.8% of samples, respec-
tively, in 1990–2012 to no samples in 2013–June 2017. 
However, the use of EQ-5D also increased from 11.1 to 
32.4% (21.3% point increase; P < 0.001), while the uses of 
the non-reference CHU9D (34.5% point increase; P < 0.001) 
and VAS approaches (12.3% point increase; P < 0.001) both 
increased.
Associations between methodological factors
Table 6 displays the association between valuation method, 
target age and three other methodological factors—respond-
ent type, administration mode and valuation of hypothetical 
health states. In all four tests, there is significant evidence 
to reject the null hypothesis of no association, with P values 
all less than 0.001. Results suggest that VAS approaches 
are more likely to be used in pre-adolescent samples and to 
be assessed by children themselves using self-administered 
surveys. However, VAS approaches are also more likely to 
be used to assess hypothetical rather than experienced health 
states. Trade-off-based direct valuation methods are more 
likely to be used in older adolescent samples and/or involve 
proxy assessment. They are also more likely to be admin-
istered by interview and for assessing hypothetical health 
states. The associative patterns varied for the three catego-
ries of MAUIs. Adult-specific MAUIs were more likely to 
be used in adolescent samples, while MAUIs compatible 
with or specific to childhood populations were both more 
likely to be used in pre-adolescent samples. Adult-specific 
MAUIs were more likely to involve self-assessment by chil-
dren, and MAUIs compatible with both populations more 
likely to involve proxy assessment. All MAUI categories 
were more likely to be self-administered than interviewer-
administered and be used to assess experienced rather than 
hypothetical health states.
Discussion
This study represents the most comprehensive systematic 
review of primary studies reporting health utilities for child-
hood conditions, covering all studies published up to 30 June 
2017. All ICD-10 chapters relevant to childhood health, 
23 valuation methods, all childhood ages, 12 respondent 
types, 8 administration modes and 42 country settings were 
observed across 3974 samples from 335 studies. There were 
strong upward linear trends in numbers of utility studies 
and samples and PEDE CUAs. There was no statistically 
significant association between numbers of PEDE CUAs 
and utility studies and samples after controlling for linear 
trend. Adopting year 2009 (when CUA became the promi-
nent analytic approach for paediatric economic evaluations 
[24]) as a key transition point, the study found evidence 
of significant changes in composition of primary samples 
across health condition, valuation method and other meth-
odological factors. There was also evidence of more refined 
approaches in primary utility research as reflected by greater 
pre-adolescent population coverage, target age reporting and 
valuation of experienced health states. For a subset of UK 
samples and using the year 2013 as a transition point (when 
NICE HTA guidance [2] was published), there was weak 
evidence that primary utility research adhered to national 
guidance. Finally, tests of association found that sample age, 
Fig. 3  Number of studies and 
samples from 1990–June 2017 
and CUAs in PEDE 1990–2016. 
Note Category 2017 denotes 
papers published up to 30th 
June 2017; PEDE: Paediatric 
Economic Database Evaluation; 
CUAs: cost–utility analyses; 
NICE: National Institute for 
Health and Care Excellence
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Table 4  Periodic change in proportion of studies and samples in each study design and sample characteristic category
Category Number (%) of studies/samples Test of proportion
1990–June 2017 1990–2008 2009–June 2017 Direction 
of change
P value
Study design Patient case  seriesa 47 (14.6) 24 (21.4) 25 (11.2) _ 0.013
Cross-sectional  surveyb 171 (51.0) 57 (50.9) 114 (51.1) + 0.972
Longitudinal studies and RCTs without CUA c 47 (14.0) 14 (12.5) 33 (14.8) + 0.568
Longitudinal studies and RCTs with CUA 
and decision models with primary utility 
 assessmentd
68 (20.3) 17 (15.2) 51 (22.9) + 0.099
Total 335 112 223
Health condition General health 501 (12.6) 41 (2.9) 460 (18.0) + < 0.001
ICD-10 chapter 1: Infectious and parasitic 
diseases
195 (4.9) 143 (10.0) 52 (2.0) _ < 0.001
ICD-10 chapter 2: Cancer 442 (11.1) 329 (23.1) 113 (4.4) _ < 0.001
ICD-10 chapter 3: Diseases of the blood and 
immune system
85 (2.1) 49 (3.4) 36 (1.4) _ < 0.001
ICD-10 chapter 4: Endocrine, nutritional and 
metabolic disorders
411 (10.3) 77 (5.4) 334 (13.1) + < 0.001
ICD-10 chapter 5: Mental and behavioural 
disorders
698 (17.6) 140 (9.8) 558 (21.9) + < 0.001
ICD-10 chapter 6: Nervous system disorders 114 (2.9) 18 (1.3) 96 (3.8) + < 0.001
ICD-10 chapter 7: Diseases of the eye 61 (1.5) 51 (3.6) 10 (0.4) _ < 0.001
ICD-10 chapter 8: Diseases of the ear 158 (4.0) 70 (4.9) 88 (3.4) _ 0.020
ICD-10 chapter 9: Circulatory system disorders 16 (0.4) 10 (0.7) 6 (0.2) _ 0.014
ICD-10 chapter 10: Respiratory system disor-
ders
192 (4.8) 37 (2.6) 155 (6.1) + < 0.001
ICD-10 chapter 11: Digestive system disorders 60 (1.5) 5 (0.4) 55 (2.2) + < 0.001
ICD-10 chapter 12: Diseases of the skin 26 (0.7) 19 (1.3) 7 (0.3) _ < 0.001
ICD-10 chapter 13: Musculoskeletal system 
disorders
114 (2.9) 42 (3.0) 72 (2.8) _ 0.717
ICD-10 chapter 14: Genitourinary system 
disorders
56 (1.4) 7 (0.5) 49 (1.9) + < 0.001
ICD-10 chapter 16: Conditions originating in 
the perinatal period
210 (5.3) 121 (8.5) 89 (3.5) _ < 0.001
ICD-10 chapter 17: Congenital malformations 155 (3.9) 16 (1.1) 139 (5.4) + < 0.001
ICD-10 chapter 19: Injury, poisoning and other 
consequences of external causes
297 (7.5) 211 (14.8) 86 (3.4) _ < 0.001
ICD-10 chapter 21: Contact with health ser-
vices
80 (2.0) 10 (0.7) 70 (2.7) + < 0.001
Combined chronic diseases 103 (2.6) 27 (1.9) 76 (3.0) + 0.037
Total 3974 1423 2551
Valuation method Visual analogue  scalese 832 (20.9) 230 (16.2) 602 (23.6) + < 0.001
Trade-off-based direct valuation  methodsf 541 (13.6) 337 (23.7) 204 (8.0) _ < 0.001
Adult-specific  MAUIsg 476 (12.0) 130 (9.1) 346 (13.6) + < 0.001
MAUIs compatible with childhood and adult 
 populationsh
1537 (38.7) 660 (46.4) 877 (34.4) _ < 0.001
Childhood-specific  MAUIsi 573 (14.4) 63 (4.4) 510 (20.0) + < 0.001
Utility from non-preference-based  methodsj 15 (0.4) 3 (0.2) 12 (0.5) + 0.147
Total 3974 1423 2551
Respondent type Self-assessment by children 1498 (37.7) 318 (22.3) 1180 (46.3) + < 0.001
Proxy assessment (includes joint assessment by 
proxies and children)
2476 (62.3) 1105 (77.7) 1371 (53.7) _
Total 3974 1423 2551
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respondent type, administration mode and valuation of hypo-
thetical health state varied significantly by valuation method.
Previous systematic reviews of primary studies assessing 
childhood health utilities have largely focused on specific 
diseases [27–31] or valuation methods [32]. Reviews that 
assembled data across heterogenous childhood health condi-
tions, valuation methods and other methodological factors 
are few. A review by Tarride and colleagues [54] included 
77 studies measuring utilities published before 2008, but 
limited its scope to asthma, cancer, combined chronic dis-
eases, diabetes and skin disease and to a limited number 
of valuation methods, namely HUI, EQ-5D, SG and TTO. 
Temporal patterns in included studies and samples were not 
explored. A review by Thorrington and Eames [55] included 
90 studies published in 1994–2013 measuring childhood 
health utilities using direct or indirect valuation methods. 
Temporal patterns in the data led to similar findings to this 
review: adult-specific valuation methods increased in use 
despite the availability of childhood-specific measures, 
whilst childhood-derived tariffs were seldom applied. How-
ever, the data were not categorised by health condition or 
age of sample, and statistical tests were not performed to 
evaluate the variations over time or associations between 
factors. Finally, a review by Kwon and colleagues [38] used 
the same search strategy to identify 272 studies published 
by 31 December 2015, thus overlapping significantly in data 
sources with this study. However, their descriptive and sta-
tistical analyses focused on non-temporal patterns in studies 
and samples and on associations between mean utility values 
and health conditions and methodological factors through 
meta-regression. Moreover, no comparison was made to 
PEDE CUAs, whilst the impact of HTA methods guidance 
on primary research was not assessed.
To our knowledge, this review is the first to summarise the 
distribution of all mean and median utility scores relevant to 
childhood health. The results show a clear disparity in dis-
tributional features between alternative central statistics of 
mean and median utilities. The ceiling effect, known to be 
significant in distributions of individual-level utility data [56], 
was visible in the distribution of medians but small in that of 
means. Negative skew in individual-level utility would pro-
duce downward adjustment of means relative to medians, and 
this is likely reflected in the less pronounced ceiling effect in 
the distribution of means. Caution is thus warranted when 
All values in bold are signify statistically significant results, i.e. p < 0.05
a Utility assessment carried out for a set period of time in a healthcare institution setting on attending patients or inpatients
b Surveys of varying modes of administration such as mail or internet
c Longitudinal observational studies include prospective and retrospective studies
d Cost–utility analyses alongside prospective or retrospective observational studies or RCTs and decision modelling studies which carry out pri-
mary collection of childhood utility data
e Stand-alone VAS, EQ-5D VAS and EQ-5D-Y VAS
f TTO, SG, Chained Gamble and adjusted SG
g EQ-5D, SF-6D, AQoL-5D and 15D
h QWB, HUI2, HUI3, modified HUI and ABC-UI
i EQ-5D-Y, CHU9D, 16D, 17D, AQoL-6D, PAHOM and CH-6D
j See [46–50]
Table 4  (continued)
Category Number (%) of studies/samples Test of proportion
1990–June 2017 1990–2008 2009–June 2017 Direction 
of change
P value
Administration 
mode
Self-administered surveys 2464 (62.0) 609 (42.8) 1855 (72.7) + < 0.001
Interview-administered surveys 1510 (38.0) 814 (57.2) 696 (27.3) _
Total 3974 1423 2551
Valuation of hypo-
thetical state
Experienced health state 3247 (81.7) 1009 (70.9) 2238 (87.7) + < 0.001
Hypothetical health state 727 (18.3) 414 (29.1) 313 (12.3) _
Total 3974 1423 2551
Age of target popu-
lation
Sample contains pre-adolescents (mean or 
median age below 12 or minimum age below 
12 if mean/median age not reported)
2086 (52.5) 708 (49.8) 1378 (54.0) + 0.011
Sample does not contain pre-adolescents 1315 (33.1) 445 (31.3) 870 (34.1) + 0.072
Sample age not specified 573 (14.4) 270 (19.0) 303 (11.9) _ < 0.001
Total 3974 1423 2551
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using aggregate or pooled outcomes in economic evalua-
tions since they contain heterogeneous distributional features 
depending on central statistic chosen, which may also differ 
from the distribution of individual-level data [57]. The distri-
butional skew also varied by valuation method, with means 
and medians from trade-off-based direct valuation methods 
(TTO, SG and variants) concentrated at the upper end of the 
utility range. This is consistent with several meta-regression 
studies [58–61] on health utilities for diverse conditions, 
which also show higher utilities from TTO and SG than from 
other valuation approaches, potentially due to biases in mak-
ing trade-offs such as loss and risk aversions [62].
The review is also the first to categorise all primary 
samples by ICD-10 chapter and code and document their 
compositional changes over time. Ascertaining how well the 
distribution of utility samples by ICD-10 chapter reflects 
prevalence of health needs in children is of interest. Were 
and colleagues [63] noted transitions in childhood morbidity 
patterns from infectious diseases to congenital anomalies, 
injuries and non-communicable diseases, including obesity, 
diabetes, cancer and respiratory diseases, while Laski and 
colleagues [64] highlighted mental health as an emerging 
priority for adolescent populations. These observations are 
reflected in our review data: the proportion of samples for 
infectious diseases fell across two primary time periods, 
1990–2008 and 2009–June 2017, while the proportions 
for endocrine, nutritional and metabolic disorders, mental 
and behavioural disorders, respiratory system disorders and 
congenital malformations increased significantly, although 
those for cancer and injuries fell. The distribution of sam-
ples by health condition can also be compared to the focus 
of paediatric CUAs. Although the latter may reflect policy 
interest more than underlying health needs, collection of 
primary data should support such secondary research. The 
report by Sullivan and Ungar [65] catalogued the distribu-
tion of paediatric CUAs by ICD-9/10 chapter. Infectious dis-
eases remained the dominant topic, accounting for 40.6% 
of all paediatric CUAs between 1980 and 2013. This was 
Table 5  UK samples by valuation method and period before and after 2013 NICE guideline
All values in bold are signify statistically significant results, i.e. p < 0.05
a Mean or median age below 12 or minimum age below 12 if mean/median age not reported; note that NICE in the UK recommends EQ-5D for 
adolescents aged 13 and over and EQ-5D-Y for children aged 7–12—this creates a subtle difference in the age range of pre-adolescence between 
this study and NICE guidance
Category Valuation method Number of samples (%) Test of proportion
1990–2012 2013–June 2017 Direction of 
change
P value
Sample contains pre-adolescentsa
 Reference for adult population EQ-5D 23 (11.1) 48 (32.4) + < 0.001
 Reference for childhood population EQ-5D-Y 8 (3.9) 25 (16.9) + < 0.001
 MAUIs compatible with childhood populations HUI2 50 (24.2) 0 (0.0)
HUI3 106 (51.2) 0 (0.0)
Total 156 (75.4) 0 (0.0) − < 0.001
 Childhood-specific MAUIs CHU9D 0 (0.0) 51 (34.5) + < 0.001
 VAS 8 (3.9) 24 (16.2) + < 0.001
 Trade-off direct valuation methods 12 (5.8) 0 (0.0) − 0.003
 Sub-total (% of total) 207 (45.0) 148 (85.1) + < 0.001
Sample does not contain pre-adolescents
 Reference for adult population EQ-5D 12 (6.6) 9 (34.6) + < 0.001
 Reference for childhood population EQ-5D-Y 15 (8.3) 4 (15.4) + 0.241
 Adult-specific MAUIs SF-6D 0 (0.0) 2 (7.7) + < 0.001
 MAUIs compatible with childhood populations HUI2 11 (6.1) 2 (7.7)
HUI3 58 (32.0) 6 (23.1)
Total 69 (38.1) 8 (30.8) − 0.471
 VAS 38 (21.0) 3 (11.5) − 0.256
 Trade-off direct valuation methods 47 (26.0) 0 (0.0) − 0.003
 Sub-total (% of total) 181 (39.3) 26 (14.9) − < 0.001
Sample did not report age of target population
 Sub-total (% of total) 72 (15.7) 0 (0.0) − < 0.001
Total 460 174
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followed by nervous system disorders (8.9%), respiratory 
system disorders (7.8%) and diseases of the blood (5.9%). 
This contrasts with our observations for utility data, with 
the above categories only accounting for 4.9%, 2.9%, 4.8% 
and 2.1% of samples, respectively. Mental health accounted 
for the largest share of utility samples (17.6%) but just 4.3% 
of paediatric CUAs. The lack of concordance is consistent 
with the lack of association found between the number of 
paediatric CUAs and numbers of utility studies and samples, 
controlling for linear trend. Future studies should assess the 
extent to which primary utility data facilitate CUAs and the 
extent to which CUAs motivate primary utility research.
Another contribution of the review is documenting the 
change in patterns of valuation method over time. A clear 
pattern was visible in the movement away from trade-off-
based direct valuation methods towards MAUIs that require 
only simple responses on a classification system and separate 
valuations using tariffs derived from representative popula-
tions. The proportion of samples using trade-off-based direct 
valuation methods fell from 23.7% in 1990–2008 to 8.0% in 
2009–June 2017, whereas the proportion of samples using 
MAUIs of any type increased from 59.9% in 1990–2008 to 
67.9% in 2009–June 2017. This perhaps reflects the concern 
over feasibility of applying cognitively demanding assess-
ments in children [15], as well as the increasing number of 
national guidelines that recommend MAUIs over direct valu-
ation methods [2–6]. The most significant growth occurred 
for childhood-specific MAUIs, which increased from 4.4% 
of samples in 1990–2008 to 20.0% in 2009–June 2017. Tests 
of association also showed that childhood-specific MAUIs 
were more likely to be self-assessed, self-administered and 
focussed on experienced health states. The question remains 
Table 6  Association between valuation method and (1) age of sample; (2) respondent type; (3) administration mode and (4) valuation of hypo-
thetical states
All values in bold are signify statistically significant results, i.e. p < 0.05
*Samples with mean or median age below 12 or minimum age below 12 (if mean/median age not reported)
** Observed number of samples (Expected number of samples). Cells in bold denote cases where observed number is greater than expected
*** Includes joint assessment by proxies and children
Visual 
analogue 
scales
Trade-off-based 
direct valuation 
methods
Adult-
specific 
MAUIs
MAUIs compat-
ible with child-
hood and adult 
populations
Childhood-
specific 
MAUIs
Utility from non-
preference-based 
methods
Total Chi-square test 
statistic
(P value)
(1) Age of sample
 Sample contains 
pre-adoles-
cents*
486**
(471.7)
152
(231.2)
250
(284.0)
751
(740.3)
443
(349.6)
4
(9.2)
2086 154.4
(< 0.001)
 Sample does not 
contain pre-
adolescents
283
(297.3)
225
(145.8)
213
(179.0)
456
(466.7)
127
(220.4)
11
(5.8)
1315 5 degrees of 
freedom
 Total 769 377 463 1207 570 15 3401
(2) Respondent type
 Self-assessment 
by children
353
(313.6)
140
(203.9)
220
(179.4)
337
(579.4)
439
(216.0)
9
(5.7)
1498 590.3
(< 0.001)
 Proxy assess-
ment***
479
(518.4)
401
(337.1)
256
(296.6)
1200
(957.6)
134
(357.0)
6
(9.3)
2476 5 degrees of 
freedom
 Total 832 541 476 1537 573 15 3974
(3) Administration mode
 Self-adminis-
tered surveys
580
(515.9)
80
(335.4)
321
(295.1)
1036
(953.0)
438
(355.3)
9
(9.3)
2464 608.6
(< 0.001)
 Interview-
administered 
surveys
252
(316.1)
461
(205.6)
155
(180.9)
501
(584.0)
135
(217.7)
6
(5.7)
1510 5 degrees of 
freedom
 Total 832 541 476 1537 573 15 3974
(4) Valuation of hypothetical states
 Experienced 
health states
582
(679.8)
152
(442.0)
450
(388.9)
1513
(1255.8)
535
(468.2)
15
(12.3)
3247 > 1500.0
(< 0.001)
 Hypothetical 
health states
250
(152.2)
389
(99.0)
26
(87.1)
24
(281.2)
38
(104.8)
0
(2.7)
727 5 degrees of 
freedom
 Total 832 541 476 1537 573 15 3974
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as to whether this represents an unambiguous improvement 
in childhood health utility assessment. Childhood-specific 
MAUIs have psychometric properties suited to children 
[15–19] and are recommended by some decision-making 
bodies [2, 6]. However, this raises a concern over compa-
rability of their utilities to those of adult-specific MAUIs, 
particularly when used as inputs into life-course decision 
models. Moreover, a review of childhood-specific MAUIs 
found no study that maps across childhood- and adult-spe-
cific utilities [22].
The above concern over comparability may explain the 
finding that the publication of HTA guidance by NICE had 
a mixed effect on primary utility assessments. In the UK 
samples containing pre-adolescent populations, the propor-
tion using the adult-specific EQ-5D increased by more than 
the proportion using the childhood-specific EQ-5D-Y after 
the guidance publication in 2013. Adlard and colleagues 
[66], after reviewing 43 paediatric CUAs set in the UK and 
published between 2004 and 2010, noted the paucity of 
childhood-specific utility data, and recommended increased 
funding for primary research that would follow NICE guid-
ance. There is only weak evidence that this has occurred 
since 2013. It is conceivable that NICE guidance may have 
encouraged the use of an adult-specific reference instrument 
(i.e. EQ-5D) in both primary and secondary research, par-
ticularly for life-course models that prioritise comparability 
of utility scores over the whole age spectrum.
This study also catalogues all tariffs applied to MAUI-
based studies, the population from whom they were 
derived and their valuation method. Around one-quarter 
(23.7%) of samples using MAUIs provided no information 
on the tariff applied, and this proportion increased from 
19.2% in 1990–2008 to 26.0% in 2009–June 2017. Among 
samples that used MAUIs compatible with or specific to 
childhood populations, 60.0% applied adult-derived tariffs, 
and this proportion increased from 50.3% in 1990–2008 to 
64.6% in 2009–June 2017. Only one sample using the EQ-
5D-Y applied childhood-derived tariffs, while none was 
available for the HUI3. However, it is difficult to conclude 
that application of childhood-derived tariffs is more appro-
priate than adult-derived tariffs even for MAUIs compat-
ible with or specific to childhood populations. Children are 
not autonomous legal, social and economic agents and do 
not bear the burden of financing public healthcare. Hence 
their preferences, even when conflicting with those of the 
general adult public, may arguably be of less importance. 
That said, analysts should recognise that applications of 
childhood and adult-derived tariffs may produce enough 
variation in utility values to alter policy decisions [67]. 
They should therefore include utility values from both 
tariffs where they are available in sensitivity analysis to 
observe the impact of alternative tariff populations.
One potential-related research area is assessing the qual-
ity of utility research and its improvement over the review 
period. However, the tests of association between sample-
level characteristics showed that choice in one methodo-
logical area (e.g. use of proxy assessment) was strongly 
associated with other methodological choices (e.g. use of 
cognitively challenging trade-off-based method) and target 
population age, which makes it challenging to assess qual-
ity and its improvement in terms of methodological choices 
(e.g. the proportion of samples using proxy assessment). 
This is more so in the absence (to our knowledge) of any 
validated quality assessment tool for primary utility stud-
ies. That said, the increase in the proportion of samples 
reporting target population age over the review period was 
an unambiguous improvement, as was the decrease in the 
proportion of samples valuing hypothetical health states 
that may result in significant overestimation of disease 
burden relative to valuation of experienced health states 
in childhood [38]. There were also areas of concern. First, 
there was a lack of studies and samples set in lower and 
middle-income countries (LMICs). Only 8.2% of samples 
were from LMICs, consistent with the paucity of paedi-
atric CUAs in LMICs, despite their substantially higher 
paediatric disease burdens [68, 91]. Among LMIC sam-
ples, 28.4% used VAS measures despite concerns over 
their validity for QALY construction [39], a proportion 
higher than for all samples (20.9%). Second, among the 
samples using MAUIs, 48.5% applied tariffs derived from 
populations foreign to the primary study setting, though 
the proportion fell from 51.7% in 1990–2008 to 46.9% in 
2009–June 2017. Among LMIC samples that used MAUIs, 
this proportion was 75.5%. Clearly, there is a pressing need 
for more national tariff derivation studies, and for more 
accurate reporting of tariff information in publications.
There are several limitations to the study. First, some 
eligible studies may have been missed during the system-
atic review process, even though the search strategies were 
extensively piloted to maximise sensitivity. Second, several 
studies did not report or did not clearly specify important 
covariates, such as age and comorbidities, which may affect 
utility values. Third, the broad criteria for selection of valu-
ation methods resulted in inclusion of modified forms of 
methods (e.g. for TTO, SG and HUI) and preference-based 
disease-specific instruments (e.g. PAHOM and ABC-UI), 
which complicated between-method comparisons. Fourth, 
the choice of 2009 as a transition point for all studies and 
samples was not based on potential causal or associative 
mechanisms determining the design and volume of primary 
utility research. Finally, cross-tabulations between methodo-
logical factors were limited to two-way Chi-square tests for 
association, and further research should consider application 
of multivariate regressions.
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Conclusion
This systematic review reveals significant growth in both 
volume and diversity of childhood utility studies over the 
past three decades. HTA agencies should note the weak 
adherence to guidance concerning the use of reference case 
valuation methods by primary studies. There is a need for 
studies that derive tariffs in settings relevant to primary util-
ity collection. Geographic coverage of utility assessment 
is heavily skewed to high-income countries, and further 
research in LMICs is pressing.
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